Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies

Background: Recent studies reported low rates of seroconversion response to COVID-19 vaccination in patients (pts) with hematologic malignancies (HMs). Vaccine choice among the 3 FDA-authorized products (BNT162b2/Pfizer-BioNTech, mRNA-1273/Moderna, or Ad26.COV2.S/J&J), prior therapy, and disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Ollila, Thomas A., Masel, Rebecca, Reagan, John L, Paiva, Kimberly, Lu, Shaolei, Rogers, Ralph, Zayac, Adam, Taher, Rashida, Yakirevich, Inna, Niroula, Rabin, Barth, Peter, Olszewski, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
622.Lymphomas: Translational-Non-Genetic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701442/
http://dx.doi.org/10.1182/blood-2021-144304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701442/
http://dx.doi.org/10.1182/blood-2021-144304

Ejemplares similares